The Science of Sustained Biologic Therapy: How Anti-FGF23 Improves Pediatric Height

Children with X-linked hypophosphatemia (XLH) or other FGF23-mediated disorders struggle to absorb and retain phosphate. This disrupts bone mineralization, leading to leg deformities, bone pain and impaired growth. Burosumab, a monoclonal antibody that blocks excess fibroblast growth factor 23 (FGF23), offers a modern approach: targeting the root cause to restore normal phosphate balance and support healthy height gains.

---

Understanding FGF23 and Growth in Children

• FGF23 is a hormone produced in bone that signals kidneys to excrete phosphate.
• In XLH and certain other rare bone diseases, FGF23 levels are abnormally high.
• Excess FGF23 causes:
  • Chronic low blood phosphate (hypophosphatemia)
  • Poor bone mineralization (rickets in children, osteomalacia in adults)
  • Slowed growth and leg bowing

Traditional therapy relied on oral phosphate supplements plus active vitamin D analogues. While helpful, this regimen often failed to fully normalize phosphate levels and carried risks of kidney stones, secondary hyperparathyroidism and gastrointestinal side effects.

---

Burosumab: Targeted Anti-FGF23 Therapy

Burosumab is an engineered antibody designed to bind circulating FGF23. By neutralizing FGF23, it allows the kidneys to retain phosphate and the gut to absorb more dietary phosphate. Key effects include:

• Increase in serum phosphate to within the normal range
• Enhanced bone mineralization
• Improvement in rickets severity on X-ray
• Acceleration of growth velocity

Mechanism of Action

1. Binding FGF23: Burosumab docks onto FGF23, preventing it from interacting with kidney receptors.
2. Restoring phosphate: With FGF23 neutralized, phosphate reabsorption in the kidneys increases.
3. Bone health: Higher serum phosphate supports normal mineral deposition in growing bones.

---

Pediatric Height Outcomes

Clinical trials have demonstrated meaningful height improvements in children treated with burosumab:

• Growth velocity gain: Many trials report a mean increase of 1.5–2.5 cm/year above baseline after 96 weeks of therapy.
• Height Z-score improvement: Standardized height measures (Z-scores) tend to rise by 0.3–0.6 points over one to two years.
• Rickets healing: Radiographic healing of rickets correlates with better structural support for growth plates.

These improvements typically become visible within 6–12 months of starting therapy, and continue through at least two years of follow-up.

---

Burosumab Long Term Safety Clinical Trial Data

Safety is a top concern for any chronic biologic therapy in children. Fortunately, multiple open-label and extension studies have now addressed long-term risks.

Key Findings

• Duration: Data extend up to 5 years in pediatric XLH populations.
• Adverse events: Mostly mild to moderate, including:
  • Injection site reactions (redness, pain)
  • Headache
  • Nasopharyngitis
• Serious events: Very rare; no new safety signals emerged with extended exposure.
• Antibody development: Low incidence of anti-drug antibodies, none neutralizing or clinically significant.
• Renal safety: No evidence of nephrocalcinosis worsening when monitored by ultrasound and lab tests.

Clinical Trial Highlights

• In a Phase 3 trial of children aged 1–12 years, Burosumab long term safety clinical trial data showed:
  • Sustained normalization of serum phosphate in ~80% of participants
  • Continued improvement in rickets severity scores
  • No increase in serious adverse events over 64 weeks of treatment
• An ongoing open-label extension confirms these findings out to 5 years, with stable safety and efficacy profiles.

Overall, the data reinforce that burosumab’s benefits on phosphate metabolism and growth come with a manageable safety profile under regular medical supervision.

---

Practical Considerations for Families

1. Administration

   • Delivered as a subcutaneous injection every two to four weeks, depending on age and weight.
   • Performed in a clinic, hospital or (in some cases) at home by a trained caregiver.

2. Monitoring

   • Serum phosphate, calcium and vitamin D levels before each dose.
   • Kidney ultrasound once or twice per year to check for nephrocalcinosis.
   • Growth measurements and rickets X-rays every 6–12 months.

3. Common Side Effects

   • Mild injection site ache or redness.
   • Temporary headache or fatigue.
   • These effects often lessen after the first few injections.

4. When to Contact Your Doctor

   • High fever, severe abdominal pain or muscle weakness.
   • Signs of low phosphate despite treatment: bone pain, muscle cramps.
   • Any unusual symptoms that could signal a serious reaction.

---

Long-Term Outlook

Children who maintain burosumab therapy over several years tend to:

• Achieve closer to their genetic height potential
• Experience fewer bone pain crises
• Show stable kidney health
• Require less oral phosphate and vitamin D supplements

Experts believe early initiation—ideally as soon as XLH is diagnosed—maximizes growth benefits and may reduce the need for corrective orthopedic surgeries later.

---

Next Steps and Resources

If you suspect your child’s growth pattern or bone pain is abnormal, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you decide whether to seek medical attention right away:
free, online symptom check, using the doctor approved Ubie Symptom Checker

Above all, discuss any concerns—especially those that could be life changing or serious—with your pediatrician or a pediatric endocrinologist. They can guide you through diagnosis, consider burosumab therapy and design a monitoring plan tailored to your child.

---

Conclusion

Anti-FGF23 therapy with burosumab represents a major advance for children with XLH and related phosphate-wasting disorders. By targeting the underlying hormone imbalance, it supports sustained phosphate normalization, rickets healing and meaningful height gains. Long-term clinical trial data affirm a favorable safety profile, empowering families and doctors to manage growth and bone health with confidence. Always speak to your doctor about any worrisome symptoms or decisions regarding biologic therapy.